DDInter640 DDInter1016
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unre
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Encorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifaximin
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Grepafloxacin
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Encorafenib may lead to a major life threatening interaction when taken with Grepafloxacin
Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib